A carregar...
Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial
BACKGROUND: The addition of trastuzumab (T) and lapatinib (L) to neoadjuvant chemotherapy increases the pathological complete response (pCR) rate in patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer. We investigated the efficacy of T or L with neoadjuvant che...
Na minha lista:
Main Authors: | , , , , , , , , , , , , , , |
---|---|
Formato: | Artigo |
Idioma: | Inglês |
Publicado em: |
Nature Publishing Group
2014
|
Assuntos: | |
Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3950860/ https://ncbi.nlm.nih.gov/pubmed/24457911 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2013.831 |
Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|